	US 12,465,562 B2
	Transdermal delivery complex using metal-organic framework and triblock copolymer
Hong Geun Ji, Gyeonggi-do (KR); Young Ah Park, Incheon (KR); Hae In Choi, Incheon (KR); and Yu Jin Kang, Gyeonggi-do (KR)
Assigned to H&A PHARMACHEM CO., LTD, Gyeonggi-Do (KR)
Appl. No. 17/419,384
Filed by H&A PHARMACHEM CO., LTD, Gyeonggi-do (KR)
PCT Filed Dec. 5, 2019, PCT No. PCT/KR2019/017102 § 371(c)(1), (2) Date Jun. 29, 2021, PCT Pub. No. WO2020/141741, PCT Pub. Date Jul. 9, 2020.
Claims priority of application No. 10-2018-0173580 (KR), filed on Dec. 31, 2018.
Prior Publication US 2022/0071882 A1, Mar. 10, 2022
Int. Cl. A61K 8/58 (2006.01); A61K 8/90 (2006.01); A61Q 17/04 (2006.01); A61Q 19/02 (2006.01); A61Q 19/08 (2006.01)

CPC A61K 8/58 (2013.01) [A61K 8/90 (2013.01); A61Q 17/04 (2013.01); A61Q 19/02 (2013.01); A61Q 19/08 (2013.01); A61K 2800/52 (2013.01); A61K 2800/58 (2013.01); A61K 2800/82 (2013.01)]

11 Claims

1. A composite for transdermal delivery comprising a metal-organic framework, a triblock copolymer of polyethylene glycol (PEG)-polycaprolactone (PCL)-polyethylene glycol (PEG), and a cosmetically active ingredient;

wherein the metal-organic framework is a zeolite imidazolate framework (ZIF)-8;

wherein the cosmetically active ingredient is one or more selected from the group consisting of a moisturizer, a whitening agent, an anti-wrinkle agent, a UV blocking agent, a hair growth promoter, vitamin or a derivative thereof, amino acid or peptide, an anti-inflammatory agent, an acne therapeutic agent, a microbicide, female hormone, a keratolytic agent and a natural product;

wherein an imine group of the ZIF-8 is bonded with the triblock copolymer of PEG-PCL-PEG to form the composite for improving a transdermal delivery effect; and

wherein 0.01 to 20 parts by weight of the triblock copolymer of PEG-PCL-PEG is comprised based on 10 parts by weight of the metal-organic framework.